Zai Lab to present first global data on zocilurtatug pelitecan in first-line ES-SCLC trial at ESMO 2026
ZLAB•Zai Lab plans to present the first global results from a trial of zocilurtatug pelitecan for first-line extensive-stage small cell lung cancer at the ESMO Congress on Oct. 26, 2026. The study tests the drug with atezolizumab, with or without carboplatin.
1. ESMO presentation planned
Zai Lab said an ESMO Congress 2026 poster presenting the trial data is scheduled for Oct. 26 in Madrid. The company has an investor call scheduled for Oct. 23 to discuss the presentation and the program’s next clinical steps.
